Browsing publications by Dr John Mansfield

Newcastle AuthorsTitleYearFull text
Dr Chris Lamb
Dr John Mansfield
Professor John Kirby
Association Between Response to Etrolizumab and Expression of Integrin alpha E and Granzyme A in Colon Biopsies of Patients With Ulcerative Colitis2016
Dr John Mansfield
Clinical Features and HLA Association of 5-Aminosalicylate (5-ASA)-induced Nephrotoxicity in Inflammatory Bowel Disease2016
Dr Richard Speight
Tracey Davey
Dr Kathryn White
Professor John Kirby
Dr John Mansfield
et al.
Activation of the bile acid receptor, farnesoid-x receptor, maintains gut epithelial cell morphology, possibly via inhibition of myosin light chain kinase expression2015
Dr Richard Speight
Anna Whitehead
Dr Gillian Patman
Dr John Mansfield
Dr Helen Reeves
et al.
Activation of the bile acid receptor, Farnesoid-X Receptor, may reduce Ileal Inflammatory Cytokine expression in an animal model of diet-induced obesity2015
Dr John Mansfield
Pooled Sequencing of 531 Genes in Inflammatory Bowel Disease Identifies an Associated Rare Variant in BTNL2 and Implicates Other Immune Related Genes2015
Dr John Mansfield
HLA-DQA1-HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants2014
Dr John Mansfield
Dr Chris Lamb
Professor John Kirby
Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial2014
Dr Carl Gamble
Dr Chris Lamb
Dr John Mansfield
Thiopurine withdrawal during sustained clinical remission in inflammatory bowel disease: relapse and recapture rates, with predictive factors in 237 patients2014
Dr Leslie Mitchell
Dr John Mansfield
Dr Janet McLelland
Dr Stephanie Needham
Vulval oedema: how many doctors does it take to make a diagnosis?2014
Dr John Mansfield
A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitis2013
123456789